Applicant: Andrew David Morley et al. Attorney's Docket No.: 06275-460US1 / 100928-1P US

Serial No.: 10/542,044 Filed : July 13, 2005

: 9 of 9 Page

## **REMARKS**

In reply to the office action mailed June 8, 2007, Applicants amended claims 1 and 17 and cancelled claims 4 and 18. Please consider the following remarks.

Claims 13-15 and 18 where rejected under 35 U.S.C. 112, first paragraph, as lacking enablement. Applicants amended claims 13 and 17, narrowing the claims to recite specific disorders, and cancelled claim 18. The claims specifically recited in amended claims 13 and 17 are presented in the specification and have been demonstrated to be related to IKK-2, which the claimed compounds have been demonstrated to inhibit. Applicants therefore submit that the amended claims are enabled and request that the corresponding rejections be withdrawn.

Claims 1-3, 5-10, 13-15, and 18 where objected to for containing non-elected subject matter. Applicants have amended claim 1 to remove the non-elected subject matter and therefore request that the objection be withdrawn.

Please apply any other charges or credits to deposit account 06-1050, referencing attorney docket number 06275-460US1.

Respectfully submitted,

Date: November 8, 2007 /Catherine M. McCarty/

Catherine M. McCarty

Reg. No. 54,301

Fish & Richardson P.C. 225 Franklin Street Boston, MA 02110

Telephone: (617) 542-5070 Facsimile: (617) 542-8906

21781688